Literature DB >> 20948918

Clinicopathological and immunohistochemical features of gastointestinal stromal tumors.

Yu Na Kang1, Hye Ra Jung, Ilseon Hwang.   

Abstract

PURPOSE: The purpose of this study was to evaluate the clinicopathological features and immunohistochemical features of gastrointestinal stromal tumor (GIST), and specifically the expressions of platelet derived growth factor receptor A (PDGFRA), protein kinase C theta (PKC theta), discovered on GIST-1 (DOG-1), p16 and p27.
MATERIALS AND METHODS: Total 118 patients who underwent surgical resection for GIST at our institution between Jan 1997 and Dec 2007 were retrospectively studied. Immunohistochemical staining for c-kit, PDGFRA, PKC-theta, DOG-1, p16 and p27 was performed on a tissue microarray of the 118 GIST. The clinicopathologic parameters, the disease-free survival (DFS) and the overall survival rate were analyzed along with immunohistochemistry.
RESULTS: The immunohistochemical stains for c-kit, CD34, PKC-theta, PDGFRA, DOG-1, p16 and p27 were positive in 89.8%, 72.0%, 56.8%, 94.9%, 90.7%, 69.5% and 44.1% of the tumor samples, respectively. The immunohistochemical expression of c-kit was strongly correlated with PKC-theta (p=0.000), DOG-1 (p=0.000) and CD34 (p=0.002). The DFS rate was significantly decreased for the patients with peritoneal GIST, high risk GIST, ≥10 cm-sized GIST, ≥10 mitoses/50 high power fields (HPFs) and p16 positivity (p=0.001, p=0.004, p=0.001, p=0.003 and p=0.028). GISTs ≥10 cm, epithelioid tumor cell type, and c-kit, and DOG-1 negativity were significantly associated with shorter period of overall survival (p=0.048, p=0.006, p=0.000 and p=0.000).
CONCLUSION: The expression of p16 and no expression of c-kit and DOG-1 in GISTs, as well as peritoneal tumor site, high risk group, large tumor size, epithelioid tumor cell type and numerous mitoses, may be potentially prognostic factors for predicting worse outcome for patients who suffer from GIST.

Entities:  

Keywords:  Gastrointestinal stromal tumors; Immunohistochemistry; Prognosis

Year:  2010        PMID: 20948918      PMCID: PMC2953776          DOI: 10.4143/crt.2010.42.3.135

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  24 in total

1.  Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.

Authors:  Norimoto Nakamura; Hidetaka Yamamoto; Takashi Yao; Yoshinao Oda; Ken-ichi Nishiyama; Masakazu Imamura; Tomomi Yamada; Hajime Nawata; Masazumi Tsuneyoshi
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

Review 2.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

Review 3.  Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Authors:  I Pidhorecky; R T Cheney; W G Kraybill; J F Gibbs
Journal:  Ann Surg Oncol       Date:  2000-10       Impact factor: 5.344

4.  Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).

Authors:  Heikki Joensuu
Journal:  Med Klin (Munich)       Date:  2002-01-15

5.  PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors.

Authors:  Atsushi Motegi; Shinji Sakurai; Hiroko Nakayama; Takaaki Sano; Tetsunari Oyama; Takashi Nakajima
Journal:  Pathol Int       Date:  2005-03       Impact factor: 2.534

Review 6.  Gastrointestinal stromal tumours.

Authors:  E M Connolly; E Gaffney; J V Reynolds
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

7.  A c-kit-negative gastrointestinal stromal tumor with a platelet-derived growth factor receptor alpha mutation.

Authors:  Jorge C Isaac; Carlynn Willmore; Joseph A Holden; Lester J Layfield
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-03

8.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

Review 10.  KIT mutations in GIST.

Authors:  Jonathan A Fletcher; Brian P Rubin
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

View more
  20 in total

1.  A Rare Case of Gastrointestinal Stromal Tumour in Pregnancy Presenting with Upper Gastrointestinal Bleeding.

Authors:  U Parampalli; C Crossland; J Longley; I Morrison; M Sayegh
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Endoscopic therapy for gastric stromal tumors originating from the muscularis propria.

Authors:  Liu-Ye Huang; Jun Cui; Yun-Xiang Liu; Cheng-Rong Wu; De-Liang Yi
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

3.  EUS for choosing best endoscopic treatment of mesenchymal tumors of upper gastrointestinal tract.

Authors:  Xin-Xin Zhou; Feng Ji; Liang Xu; Lin Li; Yi-Peng Chen; Jing-Jing Lu; Chun-Wei Wang; Wei Huang
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

4.  Compound gastroenteropancreatic neuroendocrine and gastrointestinal stromal tumors in the stomach: A case report.

Authors:  Y U Zhou; Ping Chen; Liang Zhong
Journal:  Oncol Lett       Date:  2015-09-02       Impact factor: 2.967

5.  Retrospective study of endoscopic submucosal tunnel dissection (ESTD) for surgical resection of esophageal leiomyoma.

Authors:  Lei Wang; Wei Ren; Zhimei Zhang; Jing Yu; Yihui Li; Yuankun Song
Journal:  Surg Endosc       Date:  2013-08-17       Impact factor: 4.584

6.  Intra-abdominal desmoid tumor difficult to distinguish from a gastrointestinal stromal tumor: report of two cases.

Authors:  Norihito Ogawa; Hideaki Iseki; Hidefumi Tsunozaki; Mikiko Hayashi; Hironobu Baba; Takatoshi Matsuyama; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Surg Today       Date:  2013-08-20       Impact factor: 2.549

7.  Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report.

Authors:  Daigo Yamamoto; Yoshinori Hamada; Yu Tsubota; Katsuhiro Kawakami; Chizuko Yamamoto; Mitsuo Yamamoto
Journal:  World J Surg Oncol       Date:  2012-01-09       Impact factor: 2.754

8.  Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.

Authors:  Jing Jiang; Mei-Shan Jin; Jian Suo; Yin-Ping Wang; Liang He; Xue-Yuan Cao
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

9.  Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.

Authors:  Xuechao Liu; Haibo Qiu; Peng Zhang; Xingyu Feng; Tao Chen; Yong Li; Kaixiong Tao; Guoxin Li; Xiaowei Sun; Zhiwei Zhou
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

10.  Endoscopic full-thickness resection and laparoscopic surgery for treatment of gastric stromal tumors.

Authors:  Liu-Ye Huang; Jun Cui; Cheng-Rong Wu; Bo Zhang; Li-Xin Jiang; Xiang-Shu Xian; Shu-Juan Lin; Ning Xu; Xiao-Ling Cao; Zhi-Hua Wang
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.